Questions

293. Deputy Erin McGreehan asked the Minister for Health whether her Department considered the data protection implications of the arrangement with the Health Research Consent Declaration Committee (HRCDC) whereby it requires applicants for membership of the Committee to provide their personal data to the Committee without a statutory basis for that requirement. [49988/26]

294. Deputy Erin McGreehan asked the Minister for Health the reason the Health Research Consent Declaration Committee is able to periodically publicly invite expressions of interest for membership of the committee. [49989/26]

295. Deputy Maurice Quinlivan asked the Minister for Health to examine an appointment referral case (details supplied); and if she will make a statement on the matter. [50001/26]

296. Deputy Grace Boland asked the Minister for Health the number of WTE consultant paediatric cardiologists based at CHI Temple Street Hospital; and if she will make a statement on the matter. [50004/26]

297. Deputy Grace Boland asked the Minister for Health the number of WTE environmental health officers employed by HSE in Dublin north county formerly CH09 in 2024, 2025 and to-date in 2026, in tabular form; and if she will make a statement on the matter. [50005/26]

298. Deputy Grace Boland asked the Minister for Health the number of WTE specialist registrars in vascular surgery based at Beaumont Hospital as of 22 June 2026; if she will provide the same figure as of 30 June 2023, in tabular form; and if she will make a statement on the matter. [50006/26]

299. Deputy Grace Boland asked the Minister for Health whether GPs can currently refer directly for gynaecological pelvic MRI under the GP access to community diagnostics scheme; and if she will make a statement on the matter. [50007/26]

300. Deputy Grace Boland asked the Minister for Health the reason gynaecological pelvic MRI is not available through GP referral where other MRI indications, including orthopaedic pelvic indications, are available; and if she will make a statement on the matter. [50008/26]

301. Deputy Grace Boland asked the Minister for Health whether her Department or HSE intends to review GP access to gynaecological pelvic MRI as part of the national endometriosis framework and wider women’s health policy; and if she will make a statement on the matter. [50009/26]

302. Deputy Grace Boland asked the Minister for Health whether gynaecological pelvic MRI will be added to GP access pathways under appropriate clinical criteria; and if she will make a statement on the matter. [50010/26]

303. Deputy Grace Boland asked the Minister for Health whether the HSE will create a direct GP referral pathway to specialist gynaecological imaging for suspected endometriosis or complex pelvic disease if direct GP access is not proposed; and if she will make a statement on the matter. [50011/26]

304. Deputy Grace Boland asked the Minister for Health whether her Department has reviewed the cost and patient impact of funding endometriosis-related care abroad compared with investing in improved diagnostic and treatment pathways in Ireland; and if she will make a statement on the matter. [50012/26]

305. Deputy Robert Troy asked the Minister for Health when a person (details supplied) will receive a hospital appointment. [50013/26]

306. Deputy Michael Healy-Rae asked the Minister for Health if the S1 form requested by persons will be expedited (details supplied); and if she will make a statement on the matter. [50023/26]

307. Deputy John Paul O'Shea asked the Minister for Health for an update on the delivery of the implementation plan in response to the report entitled 'The Use of Uro-gynaecological Mesh in Surgical Procedures'; and if she will make a statement on the matter. [50054/26]

308. Deputy Paul Lawless asked the Minister for Health the reason the HSE does not fully reimburse patients who avail of the cross border directive through providers such as Kingsbridge in northern Ireland, in circumstances where those patients were on Irish public waiting lists and had been informed that their procedure would not be available within six months; and if she will make a statement on the matter. [50061/…

309. Deputy Erin McGreehan asked the Minister for Health the current status of the health technology assessment and reimbursement decision for pluvicto (lutetium-177 PSMA therapy) for the treatment of metastatic castration-resistant prostate cancer; the timeline for a final determination; and if she will make a statement on the matter. [50111/26]

310. Deputy Erin McGreehan asked the Minister for Health the steps being taken to ensure Irish patients have timely and equitable access to innovative oncology treatments, including radioligand therapies such as pluvicto; and the way Ireland compares with other EU Member States in access to such treatments. [50112/26]

311. Deputy Erin McGreehan asked the Minister for Health the current capacity within the public health system to deliver radioligand therapies, including the availability of nuclear medicine facilities, trained personnel, and radiopharmacy supports; and the plans in place to expand this capacity. [50113/26]

312. Deputy Erin McGreehan asked the Minister for Health whether her Department has undertaken or commissioned any strategic review of Ireland's nuclear medicine and radiopharmacy infrastructure; and the actions planned to develop a sustainable, indigenous capability in this area. [50114/26]

313. Deputy Erin McGreehan asked the Minister for Health if consideration is being given to developing a national strategy for radiopharmaceutical production and usage, in light of increasing global demand and supply constraints; and if she will outline any engagement with industry, academia, or international partners on this issue. [50115/26]

314. Deputy Erin McGreehan asked the Minister for Health the level of capital and operational investment allocated to nuclear medicine and advanced cancer therapies over the past five years; and the projected investment over the next five years to support emerging treatments such as radioligand therapies. [50116/26]

315. Deputy Erin McGreehan asked the Minister for Health the current number of specialists in nuclear medicine, radiopharmacy, and medical physics in Ireland; the projected workforce requirements to support expansion in radioligand therapies; and the plans to address any identified gaps. [50117/26]

316. Deputy Erin McGreehan asked the Minister for Health the supports in place to enable Irish participation in international clinical trials involving radiopharmaceuticals and targeted radionuclide therapies; and the way in which Ireland can position itself as a hub for such research. [50118/26]

317. Deputy Erin McGreehan asked the Minister for Health the extent of engagement with patient advocacy organisations, including those representing prostate cancer patients, in relation to the reimbursement and provision of new treatments such as pluvicto. [50119/26]